The Impact of China's Human Genetic Resources Regime on Biopharma MNCs

May 14, 2021 | BY

Vincent Chow

China's HGR regime has been significantly bolstered in the last two years, delaying the research and development activities of biopharma MNCs in the country

Share:

Nikita G. Sidorov/iStockphoto.com

Multinational pharmaceutical companies are reducing research and development activity in China as the government tightens access to human genetic resources (HGR) and imposes ownership control on intellectual